These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

648 related articles for article (PubMed ID: 34091867)

  • 1. Cariprazine, A Broad-Spectrum Antipsychotic for the Treatment of Schizophrenia: Pharmacology, Efficacy, and Safety.
    Laszlovszky I; Barabássy Á; Németh G
    Adv Ther; 2021 Jul; 38(7):3652-3673. PubMed ID: 34091867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of cariprazine across symptom domains in patients with acute exacerbation of schizophrenia: Pooled analyses from 3 phase II/III studies.
    Marder S; Fleischhacker WW; Earley W; Lu K; Zhong Y; Németh G; Laszlovszky I; Szalai E; Durgam S
    Eur Neuropsychopharmacol; 2019 Jan; 29(1):127-136. PubMed ID: 30470662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and Tolerability of Cariprazine in Patients with Schizophrenia: A Pooled Analysis of Eight Phase II/III Studies.
    Barabássy Á; Sebe B; Acsai K; Laszlovszky I; Szatmári B; Earley WR; Németh G
    Neuropsychiatr Dis Treat; 2021; 17():957-970. PubMed ID: 33854317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia: a pooled analysis of four phase II/III randomized, double-blind, placebo-controlled studies.
    Earley W; Durgam S; Lu K; Laszlovszky I; Debelle M; Kane JM
    Int Clin Psychopharmacol; 2017 Nov; 32(6):319-328. PubMed ID: 28692485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The safety and tolerability of cariprazine in long-term treatment of schizophrenia: a post hoc pooled analysis.
    Nasrallah HA; Earley W; Cutler AJ; Wang Y; Lu K; Laszlovszky I; Németh G; Durgam S
    BMC Psychiatry; 2017 Aug; 17(1):305. PubMed ID: 28836957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of cariprazine on hostility associated with schizophrenia: post hoc analyses from 3 randomized controlled trials.
    Citrome L; Durgam S; Lu K; Ferguson P; Laszlovszky I
    J Clin Psychiatry; 2016 Jan; 77(1):109-15. PubMed ID: 26845266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cariprazine for the Treatment of Schizophrenia: A Review of this Dopamine D3-Preferring D3/D2 Receptor Partial Agonist.
    Citrome L
    Clin Schizophr Relat Psychoses; 2016; 10(2):109-19. PubMed ID: 27440212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial.
    Durgam S; Earley W; Li R; Li D; Lu K; Laszlovszky I; Fleischhacker WW; Nasrallah HA
    Schizophr Res; 2016 Oct; 176(2-3):264-271. PubMed ID: 27427558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy of cariprazine in negative symptoms of schizophrenia: Post hoc analyses of PANSS individual items and PANSS-derived factors.
    Fleischhacker W; Galderisi S; Laszlovszky I; Szatmári B; Barabássy Á; Acsai K; Szalai E; Harsányi J; Earley W; Patel M; Németh G
    Eur Psychiatry; 2019 May; 58():1-9. PubMed ID: 30738380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the long-term safety and tolerability of cariprazine in patients with schizophrenia: results from a 1-year open-label study.
    Cutler AJ; Durgam S; Wang Y; Migliore R; Lu K; Laszlovszky I; Németh G
    CNS Spectr; 2018 Feb; 23(1):39-50. PubMed ID: 28478771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cariprazine to Treat Schizophrenia and Bipolar Disorder in Adults.
    Edinoff A; Ruoff MT; Ghaffar YT; Rezayev A; Jani D; Kaye AM; Cornett EM; Kaye AD; Viswanath O; Urits I
    Psychopharmacol Bull; 2020 Sep; 50(4):83-117. PubMed ID: 33012874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cariprazine: A Review in Schizophrenia.
    Garnock-Jones KP
    CNS Drugs; 2017 Jun; 31(6):513-525. PubMed ID: 28560619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cariprazine in schizophrenia: clinical efficacy, tolerability, and place in therapy.
    Citrome L
    Adv Ther; 2013 Feb; 30(2):114-26. PubMed ID: 23361833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Term Remission With Cariprazine Treatment in Patients With Schizophrenia: A Post Hoc Analysis of a Randomized, Double-Blind, Placebo-Controlled, Relapse Prevention Trial.
    Correll CU; Potkin SG; Zhong Y; Harsányi J; Szatmári B; Earley W
    J Clin Psychiatry; 2019 Jan; 80(2):. PubMed ID: 30695290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cariprazine - a novel antipsychotic drug and its place in the treatment of schizophrenia.
    Misiak B; Bieńkowski P; Samochowiec J
    Psychiatr Pol; 2018 Dec; 52(6):971-981. PubMed ID: 30659560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cariprazine, a new type - dopamine D₃ receptor preferring - partial agonist atypical antipsychotic for the treatment of schizophrenia and the primary negative symptoms].
    Laszlovszky I; Kiss B; Barabassy A; Kapas M; Nemeth G
    Neuropsychopharmacol Hung; 2019 Sep; 21(3):103-118. PubMed ID: 31537751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and tolerability of cariprazine in the long-term treatment of schizophrenia: results from a 48-week, single-arm, open-label extension study.
    Durgam S; Greenberg WM; Li D; Lu K; Laszlovszky I; Nemeth G; Migliore R; Volk S
    Psychopharmacology (Berl); 2017 Jan; 234(2):199-209. PubMed ID: 27807604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial.
    Durgam S; Starace A; Li D; Migliore R; Ruth A; Németh G; Laszlovszky I
    Schizophr Res; 2014 Feb; 152(2-3):450-7. PubMed ID: 24412468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of cariprazine, a novel antipsychotic, on cognitive deficit and negative symptoms in a rodent model of schizophrenia symptomatology.
    Neill JC; Grayson B; Kiss B; Gyertyán I; Ferguson P; Adham N
    Eur Neuropsychopharmacol; 2016 Jan; 26(1):3-14. PubMed ID: 26655189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [(11)C]-(+)-PHNO.
    Girgis RR; Slifstein M; D'Souza D; Lee Y; Periclou A; Ghahramani P; Laszlovszky I; Durgam S; Adham N; Nabulsi N; Huang Y; Carson RE; Kiss B; Kapás M; Abi-Dargham A; Rakhit A
    Psychopharmacology (Berl); 2016 Oct; 233(19-20):3503-12. PubMed ID: 27525990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.